Home / Business and Economy / Novo Nordisk and Emcure Team Up to Boost Access to Weight-Loss Drug in India
Novo Nordisk and Emcure Team Up to Boost Access to Weight-Loss Drug in India
10 Nov
Summary
- Novo Nordisk partners with Emcure to distribute weight-loss drug semaglutide in India
- Semaglutide to be launched under new brand name 'Poviztra' as a 2.4mg weekly injection
- Collaboration aims to enhance accessibility in India's fast-growing anti-obesity drug market
On November 10, 2025, Danish pharmaceutical company Novo Nordisk announced an exclusive partnership with Pune-based Emcure Pharmaceuticals to widely distribute its weight-loss therapy semaglutide in India. The two companies will launch semaglutide under a new brand name, Poviztra, as a 2.4mg weekly injection.
The move comes as competition heats up in India's fast-growing anti-obesity drug market. Last month, US drug giant Eli Lilly announced a similar tie-up with Mumbai-based Cipla to distribute its anti-obesity medication Tirzepatide. Novo Nordisk and Emcure have not yet revealed the pricing strategy or launch date for Poviztra, but have promised to be "very competitive" in their pricing.
Novo Nordisk currently markets semaglutide in India under the brand names Wegovy and Rybelsus. The idea behind partnering with a domestic player like Emcure is to increase scale and access pockets of patients beyond Novo's existing reach, particularly in smaller towns and rural areas. Emcure's extensive distribution network and 5,000-strong medical representative team are expected to help expand the drug's availability across India.
